Why Stem Cells Work: Clinical Trials for Spinal Cord Injury, Multiple Sclerosis, Rheumatoid Arthritis, and Duchenne’s Muscular Dystrophy

Neil Riordan, PhD speaks at the Riordan-McKenna Institute and Stem Cell Institute fall seminar in Southlake, Texas on October 10, 2015.

Dr. Riordan discusses:

  • How our lab selects uses specialized screening techniques to select only the stem cells that we know will be the most useful for our patients. Only about 1 in 100 cords pass this screening process.
  • How umbilical cord mesenchymal stem cells (MSC) control inflammation, modulate the immune system and stimulate regeneration.
  • How the number and function of our own stem cells decline over time.
  • How MSC secretions promote healing
  • Where MSCs are found in our body
  • First clinic trial in the US using umbilical cord tissue-derived stem cells
  • How MSC doubling times dramatically decrease as people age, which is why cord cells are much more robust than a patient’s own cells as they age
  • The origin of Medistem Lab in Panama
  • Why the Stem Cell Institute and Medistem Labs are in Panama
  • Stem cell therapy laws and approvals around the world
  • Global interest in mesenchymal stem cell therapy research
  • Current clinical trials using mesenchymal stem cells
  • Clinical trials in Panama
  • Collaborations with corporations and educational institutions
  • Mesenchymal stem cell selection, donor selection, and testing
  • Brief tour of Medistem Panama stem cell laboratory
  • Isolation and production of mesenchymal stem cells
  • Discovery of mesenchymal stem cells in menstrual blood
  • Umbilical cord mesenchymal stem cell studies for rheumatoid arthritis
  • The role of T-regulatory cells in rheumatoid arthritis and multiple sclerosis
  • Treating spinal cord injuries with mesenchymal stem cells
  • Mechanism of mesenchymal stem cells on spinal cord injury. They are not becoming tissue. It’s their secretions that allow the spinal cord to heal itself.
  • Umbilical cord MSC studies on spinal cord injury
  • Data from Stem Cell Institute spinal cord injury patients
  • Video from treated spinal cord injury patients
  • Postnatal MSC safety
  • MSCs and cancer risk – MSCs have been shows to actually inhibit tumor growth

Stem Cell-Augmented Achilles Tendon Rupture Repair Yields Excellent Results

Int Orthop. 2015 May;39(5):901-5. doi: 10.1007/s00264-015-2725-7. Epub 2015 Mar 22.

Outcomes of acute Achilles tendon rupture repair with bone marrow aspirate concentrate (BMAC) augmentation

Stein BE, Stroh DA, Schon LC.

“Excellent results, including no re-ruptures and early mobilisation, were observed…”

Abstract

Kobe-AchillesPURPOSE:
Optimal treatment of acute Achilles tendon ruptures remains controversial. Positive results using stem-cell-bearing concentrates have been reported with other soft-tissue repairs, but no studies exist on outcomes of bone marrow aspirate concentrate (BMAC) augmentation in primary Achilles tendon repair.

METHODS:
We reviewed patients with sport-related Achilles tendon ruptures treated via open repair augmented with BMAC injection from 2009 to 2011. Data on operative complications, strength, range of motion, rerupture, calf circumference and functional improvement through progressive return to sport and the Achilles tendon Total Rupture Score (ATRS) were analysed.

RESULTS:
A total of 27 patients (28 tendons) treated with open repair and BMAC injection were identified (mean age 38.3 ± 9.6 years). At mean follow-up of 29.7 ± 6.1 months, there were no reruptures. Walking without a boot was at 1.8 ± 0.7 months, participation in light activity was at 3.4 ± 1.8 months and 92% (25 of 27) of patients returned to their sport at 5.9 ± 1.8 months. Mean ATRS at final follow-up was 91 (range 72-100) points. One case of superficial wound dehiscence healed with local wound care. No soft-tissue masses, bone formation or tumors were observed in the operative extremity.

CONCLUSIONS:
Excellent results, including no re-ruptures and early mobilisation, were observed in this small cohort with open Achilles tendon repair augmented by BMAC. No adverse outcomes of biologic treatment were observed with this protocol. The efficacy of BMAC in the operative repair of acute Achilles tendon ruptures warrants further study.

LEVEL OF EVIDENCE:
IV – Therapeutic.

Ruptured Achilles Tendon Treatment at Dr. Riordan’s Clinic in Dallas-Fort Worth

At Riordan-McKenna Institute, Dr. McKenna performs a procedure for achilles tendon rupture that is similar to the one described in this study. However, Dr. McKenna augments the BMAC injection with AlphaGEMS amniotic tissue product. AlphaGEMS is a pliable tissue allograft (transplant) derived from human placental amnion, which contains over 100 growth factors and functions as a biologic structural matrix to facilitate and enhance tissue healing and repair. The inclusion of AlphaGEMS adds a new dimension to the tissue repair process.

For more information about BMAC and AlphaGEMS treatment at RMI, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

If you have suffered a ruptured achilles tendon and would like to be evaluated for treatment at RMI, the first step is to complete an online medical history. Once we receive it, our staff will contact you to answer general questions and to guide you through the rest of the evaluation process, which usually requires recent MRI images and an MRI report.

https://secureform.rmiclinic.com/forms/13299/3207/VVp7/form.html

Study on Compensated Rotator Cuff Tear Arthropathy by Orthopedic Surgeon and Stem Cell Specialist, Wade McKenna, DO Published in Techniques in Shoulder and Elbow Surgery

Dallas-Fort Worth, Texas (PRWEB) November 08, 2015

A Study by orthopedic surgeon and stem cell specialist, Dr. Wade McKenna of the Riordan-McKenna Institute entitled, “Outpatient Treatment of Compensated Cuff Arthropathy Using Inlay Arthroplasty With Subscapularis Preservation” is published in the December edition of Techniques in Shoulder and Elbow Surgery.

Picture of Dr. Wade McKenna

Dr. McKenna

Dr. McKenna is co-founder and chief medical officer of the Riordan-McKenna Institute of Regenerative Orthopedics (RMI) in Southlake, Texas. Co-author of this work is Troy Chandler, PA-C from North Central Texas Orthopedics in Decatur, Texas.

Rotator cuff tear arthropathy sometimes develops in patients who have had a very large, long-standing rotator cuff injury. In CTA, changes in the shoulder due to the rotator cuff tear cause arthritis and lead to destruction of joint cartilage.

The Shoulder HemiCAP® restoration procedure is designed to match the shape and contour of individual patient’s cartilage and joint surface and be an ideal alternative to shoulder replacement. It simply recreates a smooth surface where the cartilage has worn away — similar to a filling for a tooth cavity.

The study examined a consecutive series of 50 CTA patients treated by Dr. McKenna from 2007 to 2015. It concluded that resurfacing the humeral head (shoulder bone) using a HemiCAP shoulder implant preserves the joint and avoids bone loss and complications associated with more invasive procedures like stemmed arthroplasty or total shoulder replacement.

Furthermore, the HemiCAP procedure disrupts the degenerative cycle of early-stage CTA, effectively addresses causes of pain, and avoids further muscle imbalance. The latter is achieved by a special deltoid muscle-splitting approach that leaves the tendon under the shoulder bone intact.

All of these advantages resulted in accelerated recovery and rehabilitation for patients.

“We are very pleased with the positive outcome of this study. Although we specialize in non-surgical stem cell interventions at RMI, sometimes, as in the case of CTA, surgical intervention is indicated. That’s why it’s important for patients to seek out an experienced orthopedic surgeon who, in addition to orthopedic expertise, is well versed on the latest advances in stem cell therapy. A surgeon needs both to know when stem cell therapy may be effective and when surgery, perhaps augmented with biologics like bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product, is a better option,” commented Dr. McKenna.

About Riordan-McKenna Institute (RMI)

RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *AlphaGEMS flowable amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. RMI also uses AlphaPATCH amniotic membranes as part of a complete wound care treatment regimen.

RMI also augments orthopedic surgeries with BMAC and AlphaGEMS to promote better post-surgical outcomes.

BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.

*AlphaGEMS and AlphaPATCH products are produced by Amniotic Therapies Inc. from donated amniotic tissue after normal healthy births. For more information about AlphaGEMS, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

http://www.rmiclinic.com

801 E. Southlake Blvd.

Southlake, Texas

76092

Tel: (817) 776-8155

Toll Free: (877) 899-7836

Fax: (817) 776-8154

For the original version on PRWeb visit: http://www.prweb.com/releases/2015/11/prweb13068117.htm

PRESS RELEASE – UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute

MRI confirms complete healing of hamstring eight weeks after Dr. Wade McKenna administered guided injections of bone marrow aspirate concentrate (BMAC) harvested with BioMAC (patent pending) bone marrow aspiration cannula and AlphGEMS amniotic tissue product at the Riordan-McKenna Institute.

DALLAS-FORT WORTH, TEXAS (PRWEB) SEPTEMBER 03, 2015

Zack Bornstein with Dr. McKenna and Physicians Assistant, Troy Chandler

Zack Bornstein with Dr. McKenna and Physicians Assistant, Troy Chandler

UCLA wide receiver and Canadian decathlon standout, Zack Bornstein suffered a hamstring tear 18 months ago. Conventional treatment and therapy were not working so Zack decided to undergo stem cell therapy at Riordan-McKenna Institute in late June 2015. Dr. McKenna treated Zack with precisely guided injections of bone marrow aspirate concentrate (BMAC) harvested with the BioMAC (patent pending) bone marrow aspiration cannula and *AlphGEMS amniotic tissue product.

Complete healing was confirmed by MRI 8 weeks after treatment:

1) No evidence for hamstring strain or denervation and no evidence for tendon tear.
2) No evidence for focal atrophy or hematoma.
3) No osseous abnormalities seen.

After receiving the MRI results, Zack’s father Dean said, “I am not a doctor but looks like you and your procedure has performed a medical miracle! …Thanks for all of your efforts.”

Zack is currently a red shirt freshman at UCLA. He played football at Oaks Christian High School from 2011-’14 and lettered 3 years in football and all 4 years in track. In 2013, Zack was named to the All-Marmonte 2nd team. He played in the FBU Youth All-American game in 2010. In track, he is considered to be one of the top decathletes in the country. Zack competed at the 2013 Pan American Junior Championships in Medellin, Columbia, finishing in 5th place with 7,097 points. In July of 2013, he became the Canadian Junior National Champion (6,918 pts). Zack won the silver medal at the 2013 Arcadia Invitational Decathlon, scoring 6,967 points to set a new California state record for juniors (2nd highest score in California state history). Zack is a 12-time National Champion, 44-time All-American and a member of three National Championship cross country teams.

About Riordan-McKenna Institute (RMI)

RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *AlphaGEMS flowable amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. RMI also uses AlphaPATCH amniotic membranes as part of a complete wound care treatment regimen.

RMI also augments orthopedic surgeries with BMAC and AlphaGEMS to promote better post-surgical outcomes.
BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.

*AlphaGEMS and AlphaPATCH products are produced by Amniotic Therapies Inc. from donated amniotic tissue after normal healthy births. For more information about AlphaGEMS, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

http://www.rmiclinic.com

801 E. Southlake Blvd.
Southlake, Texas
76092

Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154

About Amniotic Therapies

Based in Dallas, Texas, Amniotic Therapies specializes in the processing and distribution of human amniotic tissue products for the biologic and regenerative medicine segments of the healthcare market. Amniotic Therapies’ mission is to provide superior human amniotic tissue products that naturally enhance the body’s healing ability, providing patients with improved healing.
Amniotic Therapies is registered with the U.S. Food and Drug Administration (FDA) and is in the process of receiving accreditation from the American Association of Tissue Banks.

http://www.amniotictherapies.com

11496 Luna Rd. Suite 800
Dallas, Texas
75235

Tel: (972) 465-0496

Case report of non-healing surgical wound treated with dehydrated human amniotic membrane

AlphaPATCH Amniotic Membrane PictureDr. Riordan and Dr. Wade McKenna recently published this case study demonstrating how amniotic tissue products promote wound healing. You can view the original article on the Journal of Translational Medicine website: Case report of non-healing surgical wound treated with dehydrated human amniotic membrane.

Authors
Neil H Riordan, Ben A George, Troy B Chandler, Randall W McKenna

Abstract

INTRODUCTION
Non-healing wounds can pose a medical challenge as in the case of vasculopathic venostasis resulting in a surgical ulcer. When traditional approaches to wound care fail, an amniotic patch (a dehydrated tissue allograft derived from human amnion) can function as a biologic scaffold to facilitate and enhance tissue regeneration and rehabilitation.

BACKGROUND
Amniotic AlphaPatches contain concentrated molecules of PGE2, WNT4, and GDF-11 which have angiogenic, trophic, and anti-inflammatory effects on tissues that may be useful in enhancing wound healing.

AIM-CASE REPORT
We present a case of a severe non-healing surgical wound in a 78-year-old male 17 days post right total knee arthroplasty. The full-thickness wound exhibited a mobile flap, measured 4 cm long × 3 cm wide, and showed undermining down to patellar tissue. We treated the wound conservatively for 6 weeks with no evidence of wound healing. Upon failure of the conservative treatment, two amniotic AlphaPatch (Amniotic Therapies, Dallas, TX, USA) were applied to the wound, and the wound healed completely in 10 weeks.

METHODS
In the OR, the wound was irrigated with three liters of double antibiotic solution under pulse lavage. Two dry amniotic AlphaPatch (4 cm × 4 cm) were placed over the wound with Acticoat applied on top.

RESULTS
At the two-week follow-up visit (following the incision and drainage of the wound dehiscence and application of the amniotic AlphaPatch), a central scab had formed centrally in the wound dehiscence area. At the four-week follow-up visit, the wound dehiscence area had completely scabbed over with no open areas left. At the eight-week follow-up visit, the scab had just fallen off, and the wound was healing well with immature skin representing the size of a penny. At the ten-week follow-up visit, the wound was completely healed.

DISCUSSION/CONCLUSION
Sterile, dehydrated amniotic tissue AlphaPatches (containing trophic factors known to enhance wound healing) have proven effective in completely healing an otherwise non-healing wound in a 78-year-old male who failed six weeks of conservative wound care treatment.

Picture of wound before treatment with AlphaPATCH amniotic membrane

Picture of wound 2 weeks after treatment with AlphaPATCH amniotic membrane

Picture of wound 4 weeks after treatment with AlphaPATCH amniotic membrane

Picture of wound 8 weeks after treatment with AlphaPATCH amniotic membrane

Picture of wound 8 weeks after treatment with AlphaPATCH amniotic membrane

PBS to Feature Stem Cell Therapy at Stem Cell Institute and Medistem Labs Panama in TV Special

PBS is in Panama this week filming Stem Cell Institute’s clinic, staff and patients. Yesterday, they toured Medistem Labs Panama. Here are a few pictures taken by Dr. Riordan at the lab. Watch for this special to air on PBS this fall.

PBS at Medistem Labs in Panama 4

PBS at Medistem Labs in Panama 3

PBS at Medistem Labs in Panama 2

PBS at Medistem Labs in Panama 1

Copa Airlines Magazine Features Stem Cell Therapy at the Stem Cell Institute in Panama

Stem Cell Therapy for Multiple Sclerosis: Ron McGill

Ron McGill suffers from relapsing-remitting multiple sclerosis. He was started experiencing symptoms in 2009 but was not diagnosed with MS until January of 2013. He received several infusion and injections of human umbilical cord-tissue derived stem cells at the Stem Cell Institute in late October and Early November 2013.

In this video, Ron shares his story of discovery and recovery at a Stem Cell Institute seminar in San Antonio in October 2014.

For more information on MS therapy at the Stem Cell Institute in Panama, please visit: https://www.cellmedicine.com/stem-cell-therapy-for-multiple-sclerosis-3/

Good afternoon.

I was diagnosed with relapsing-remitting MS in January of 2013. My symptoms started with tingling and numbness in my hands and feet migraine headaches in April, 2009. Visits to the doctors concluded that job stress-related migraines were all it was.

My high tolerance for pain accepted the results and I went on with life. This was an extremely poor decision on my part. My symptoms remained constant but non-progressing until November of 2011. In attempting to kick a soccer ball, I lost my balance and I fell. I wrote it off as being out of shape and clumsy. A fall on a treadmill and down a stairwell in early 2012 was my final wakeup call. It solidified that there was more wrong with me than normal.

My quest to find out what was causing my issues and how to resolve them was started.

Starting from behind and (inaudible) to catch up, I did several things. I made immediate dietary changes. Sodas, fast food, canned food, alcohol – eliminated. Red meat, dairy, bread, pasta – reduced drastically. Chicken, fish, fresh fruits, vegetables – doubled. I went on a weight loss and body detox regimen. I replaced impact aerobic exercises I could no longer do with swimming.

I made the most of my insurance. I literally became a human pin cushion. Everybody was sticking me. I looked outside traditional medicine: acupuncturist, building my immune system and pure vitamin regimens. While I made great strides in changing my life, I was testing healthier, a progression of worse symptoms continued to happen. Severe leg and back aches, leg stingers, twitching, lost grip and more loss of balance.

It was determined that MS was my cause. My instability had me falling one to two times a month. I reached my lowest point waking up immobile from the waist down on a Wednesday morning in February of 2013.

With my motor skills seemingly erased from my memory, a deep cloud of panic overtook me. My confidence went out the window. I had to dig down extremely deep. I was able to regain mobility later that evening. I progressed to a penguin walk and very limited speed and distance over the next 6 months with the help of a walking stick and physical therapy.
Hours of online research for possible relief led to stem cell therapy.

After many months of research, doctor consultations, numerous conversations with people who had had stem cell therapy, heard about it, had relatives who had experienced it, I sent the email to the Stem Cell Institute.

After being accepted, I still had more conversations with Dr. Barnett and Cindy, asking more and more questions. They were extremely patient to everything I had.

The care provided for me upon my arrival and during my stay and departure in Panama was extremely good. The facility was simple, clean, efficient with a very helpful and friendly staff. The procedure was well-explained to me and carefully administered.

I was able to see results on my way back (on) November 3rd. I was able to walk farther and feel better. I was able to my walking stick in the back of my car for good two weeks later. Knock on wood, I haven’t fallen since October 23rd of 2013. My stamina, walking speed and stability have continued to increase. I do have momentary balance loss and heat can still wipe me out. My MS is still with me.

Do I feel (that) Panama was the right choice? For me, absolutely. I feel the infusion of healthy cells gave my body a huge boost to recover the majority of lost motor skills I had experienced. It also helped amplify the lifestyle changes I was already making to give me a faster and more positive result.

These successes have given me a more positive mental state that have allowed me to heal more and more.

What advice could I give you about stem cells? Research, research, research. There isn’t a price you can put on due diligence when it comes to your health. Make lifestyle changes at the cellular level in your body and amplify it with stem cell therapy.

In closing, I’d like to thank my wife for undying support and hours of research. I’d like to thank Dr. Riordan, (and) Stem Cell Institute for being at the cutting edge of healing diseases and I’d like to thank you all for allowing me to share with you today.

The Lip TV News: Neil Riordan, PhD on Exploring New Stem Cell Treatments for MS, Arthritis, Autism and More

Stem cell treatment and research towards curing illness–from multiple sclerosis to spinal injury–is detailed by Dr. Neil Riordan. The American medical industry, obstructions to research in the states, misconceptions about stem cells, and the details about the treatment process are explained–and we look at video of patient recovery and speculate at what the future could spell for stem cell treatment and research in this Lip News interview, hosted by Elliot Hill.

GUEST BIO:
Dr. Neil Riordan is the founder and Chairman of Medistem Panama, a leading stem cell laboratory and research facility – located in Panama City. His institute is at the forefront of research of the effects of adult stem cells on the course of several chronic diseases. Dr. Riordan has more than 60 scientific articles in international peer-reviewed journals. In the stem cell arena, he and his colleagues have published more than 20 articles on Multiple Sclerosis, Spinal Cord Injury, Heart Failure, Rheumatoid Arthritis.

Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase

Chicago, Illinois (PRWEB) October 30, 2014

On October 26th at the Mid American Regenerative and Cellular Medicine Showcase in Chicago, leading applied stem cell research scientist Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna presented talks on New Techniques for Enhancing Stem Cell Therapy Effectiveness and Orthopedic Surgical Applications For Stem Cells.

Dr. Riordan focused on historical medical uses of amniotic membrane and the properties of AlphaGEMS that include: wound healing; inflammation and pain reduction; fibrosis risk reduction; growth factor source; adhesion reduction; regeneration support and stem cell enhancement, specifically regarding the mesenchymal stem cells contained within BMAC.

Dr. McKenna discussed the latest applications of BMAC stem cells in orthopedic surgeries like anterior cruciate ligament (ACL) reconstruction and how BMAC injections can virtually eliminate infection risk, reduce complications, increase graft strength, reduce post-surgical inflammation and significantly reduce recovery time. Dr. McKenna also talked about how bone marrow can now be safely and relatively painlessly harvested using his patented BioMAC catheter under local, not general anesthesia.

Dr. Riordan and Dr. McKenna are co-founders of the Riordan-McKenna Institute (RMI), which will be opening soon in Southlake, Texas. RMI will specialize in regenerative orthopedics including non-surgical stem cell therapy and stem cell-enhanced surgery using bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product.

Other noteworthy speakers in attendance included: Paolo Macchiarini, MD-PhD, Arnold Caplan, PhD and Mark Holterman, MD-PhD. Dr. Macchiarini and Dr. Holterman are well known for their work on the first stem cell trachea transplant. Dr. Caplan discovered the mesenchymal stem cell and is commonly referred to as the father of the mesenchymal stem cell.

About Neil Riordan PhD

Dr. Riordan is the co-founder of the Riordan-McKenna Institute (RMI), which will be opening soon in Southlake, Texas. RMI will specialize in regenerative orthopedics including non-surgical stem cell therapy and stem cell-enhanced surgery using bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product.

Dr. Riordan is founder and chief scientific officer of Amniotic Therapies Inc. (ATI). ATI specializes in amniotic tissue research and development. Its current product line includes AlphaGEMS and AlphaPATCH amniotic tissue-based products.

Dr. Riordan is the founder and chairman of Medistem Panama, Inc., (MPI) a leading stem cell laboratory and research facility located in the Technology Park at the prestigious City of Knowledge in Panama City, Panama. Founded in 2007, MPI stands at the forefront of applied research on adult stem cells for several chronic diseases. MPI’s stem cell laboratory is ISO 9001 certified and fully licensed by the Panamanian Ministry of Health. Dr. Riordan is the founder of Stem Cell Institute (SCI) in Panama City, Panama (est. 2007).

Under the umbrella of MPI subsidiary Translational Biosciences, MPI and SCI are currently conducting five IRB-approved clinical trials in Panama for multiple sclerosis, rheumatoid arthritis and osteoarthritis using human umbilical cord-derived mesenchymal stem cells, mesenchymal trophic factors and stromal vascular fraction. Additional trials for spinal cord injury, autism and cerebral palsy are slated to commence in 2014 upon IRB approval.

Dr. Riordan is an accomplished inventor; listed on more the 25 patent families, including 11 issued patents. He is credited with a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father Dr. Hugh Riordan on the effects of high-dose intravenous vitamin C on cancer cells and the tumor microenvironment. This pioneering study on vitamin Cs preferential toxicity to cancer cells notably led to a 1997 patent grant for the treatment of cancer with vitamin C. In 2010, Dr. Riordan received another patent for a new cellular cancer vaccine.

Dr. Riordan is also the founder of Aidan Products, which provides health care professionals with quality nutraceuticals including Stem-Kine, the only nutritional supplement that is clinically proven to increase the amount of circulating stem cells in the body for an extended period of time. Stem-Kine is currently sold in 35 countries.

Dr. Riordan earned his Bachelor of Science at Wichita State University and graduated magna cum laude. He received his Masters degree at the University of Nebraska Medical Center. Dr. Riordan completed his education by earning a Ph.D. in Health Sciences at Medical University of the Americas.

About Dr. Wade McKenna

Dr. Wade McKenna is cofounder of the Riordan-McKenna Institute. He is a leading advocate of Autologous Stem Cell Therapy and Regenerative Medicine focusing on advancing the clinical benefits in orthopedics.

Board certified in orthopedic surgery, Dr. McKenna is the chief medical officer and co-founder of Biologic Therapies, a product development and research company dedicated to the advancement of autologous adult stem cell therapy. His achievements include the recent development of the BioMac bone marrow aspiration catheter, treating world-class athletes, and developing numerous surgical and non-surgical stem cell application protocols.

After receiving his undergraduate degree and earning his medical degree at Oklahoma State University, Dr. McKenna completed his orthopedic residency at the Dallas/Ft Worth Medical Center and his trauma fellowship at Tampa General Hospital. With over 20 years in private practice, Dr. McKenna has successfully built McKenna Orthopedics in Trophy Club, Texas and North Central Texas Orthopedics & Sports Medicine in Decatur, Texas.

Dr. McKenna has a proven track record of producing positive clinical outcomes augmented by concentrated, autologous bone marrow aspirate. Dr. McKenna has applied this stem cell-enriched product to thousands of surgical and non-surgical patients. Successful applications include long bone non-unions; avascular necrosis of the femoral head; severe clavicle non-unions; cartilage regeneration; chondrogenesis and soft tissue repair of the shoulder; chronic tendonopathy; tendon ruptures; numerous applications to common, often difficult foot and ankle injuries; and wrists fractures.

Riordan-McKenna Institute
www.rmiclinic.com
801 E. Southlake Blvd.
Southlake, Texas
76092

Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154